Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Fineline Cube Jul 7, 2026
Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Fineline Cube Jul 7, 2026
Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Fineline Cube Jul 7, 2026
Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Fineline Cube Jul 7, 2026
Company Deals

Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration

Fineline Cube Jul 7, 2026
Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Drug

AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD

Fineline Cube May 13, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...

Company Drug

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Fineline Cube May 13, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

Fineline Cube May 12, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...

Company Medical Device

MicroPort’s Talos Stent Gains Marketing Approval in Argentina

Fineline Cube May 12, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Policy / Regulatory

Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality

Fineline Cube May 12, 2025

The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...

Company Deals

Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development

Fineline Cube May 12, 2025

China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....

Company Deals

EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products

Fineline Cube May 12, 2025

China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...

Company Drug

Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment

Fineline Cube May 12, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...

Company Deals

Eli Lilly and Purdue Expand Partnership With $250 Million Investment

Fineline Cube May 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...

Company Drug

CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study

Fineline Cube May 12, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...

Company Drug

CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction

Fineline Cube May 12, 2025

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG

Fineline Cube May 12, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...

Company Deals Drug

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

Fineline Cube May 12, 2025

China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...

Company Drug

InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL

Fineline Cube May 12, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...

Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

Fineline Cube May 12, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...

Company Drug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Fineline Cube May 12, 2025

China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...

Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Company Drug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

Fineline Cube May 12, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...

Company Drug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Posts pagination

1 … 189 190 191 … 691

Recent updates

  • cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
  • BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology
  • Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal
  • Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation
  • Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.